108 related articles for article (PubMed ID: 12495370)
1. Several apparent errors surfaced on reading the article in the June 2002 issue of Alternative Medicine Review by Kodama et al. entitled "Can maitake MD-fraction aid cancer patients"?
Black W
Altern Med Rev; 2002 Dec; 7(6):451; author reply 452-4. PubMed ID: 12495370
[No Abstract] [Full Text] [Related]
2. Can maitake MD-fraction aid cancer patients?
Kodama N; Komuta K; Nanba H
Altern Med Rev; 2002 Jun; 7(3):236-9. PubMed ID: 12126464
[TBL] [Abstract][Full Text] [Related]
3. Maitake extracts and their therapeutic potential.
Mayell M
Altern Med Rev; 2001 Feb; 6(1):48-60. PubMed ID: 11207456
[TBL] [Abstract][Full Text] [Related]
4. Anthracycline dose intensity: clinical pharmacology and pharmacokinetics of high-dose doxorubicin administered as a 96-hour continuous intravenous infusion.
Synold TW; Doroshow JH
J Infus Chemother; 1996; 6(2):69-73. PubMed ID: 8809652
[TBL] [Abstract][Full Text] [Related]
5. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
6. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer.
Rose PG
Oncologist; 2005 Mar; 10(3):205-14. PubMed ID: 15793224
[TBL] [Abstract][Full Text] [Related]
7. Effect of Maitake D-fraction on cancer prevention.
Nanba H; Kubo K
Ann N Y Acad Sci; 1997 Dec; 833():204-7. PubMed ID: 9616756
[No Abstract] [Full Text] [Related]
8. Clinical cancer chronotherapy trials: a review.
Bjarnason GA
J Infus Chemother; 1995; 5(1):31-7. PubMed ID: 7634175
[TBL] [Abstract][Full Text] [Related]
9. [Hereditary neuroendocrine gastroenteropancreatic tumors and multiple endocrine neoplasia type 1].
Scherübl H; Schaaf L; Raue F; Faiss S; Zeitz M
Dtsch Med Wochenschr; 2004 Mar; 129(13):689-92. PubMed ID: 15026965
[No Abstract] [Full Text] [Related]
10. Role of pegylated liposomal doxorubicin in ovarian cancer.
Thigpen JT; Aghajanian CA; Alberts DS; Campos SM; Gordon AN; Markman M; McMeekin DS; Monk BJ; Rose PG
Gynecol Oncol; 2005 Jan; 96(1):10-8. PubMed ID: 15589573
[TBL] [Abstract][Full Text] [Related]
11. [Metronomic chemotherapy in pediatric oncology: hype or hope?].
André N; Pasquier E; Verschuur A; Sterba J; Gentet JC; Rössler J
Arch Pediatr; 2009 Aug; 16(8):1158-65. PubMed ID: 19446445
[TBL] [Abstract][Full Text] [Related]
12. Cardiac safety profile of prolonged (>or=6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies.
Uyar D; Kulp B; Peterson G; Zanotti K; Markman M; Belinson J
Gynecol Oncol; 2004 Jul; 94(1):147-51. PubMed ID: 15262133
[TBL] [Abstract][Full Text] [Related]
13. Can a rational design for metronomic chemotherapy dosing be devised?
Maraveyas A; Lam T; Hetherington JW; Greenman J
Br J Cancer; 2005 Apr; 92(8):1588-90. PubMed ID: 15846302
[No Abstract] [Full Text] [Related]
14. Intraarterial Cisplatin and intravenous adriamycin in nonmetastatic osteosarcoma of the extremities: a single institution experience in Taiwan.
Chiu TJ; Wang JW; Chen YJ; Tang Y; Huang CH
Chang Gung Med J; 2009; 32(1):72-80. PubMed ID: 19292942
[TBL] [Abstract][Full Text] [Related]
15. A comparative randomized trial of intermittent intrahepatic arterial carboplatin- versus doxorubicin-lipiodol emulsion in advanced hepatocellular carcinoma (stage IV).
Homma H; Mezawa S; Doi T; Miyanishi K; Takada K; Kukitsu T; Oku T; Masuko E; Nojiri S; Niitsu Y
Hepatogastroenterology; 2004; 51(58):1135-9. PubMed ID: 15239261
[TBL] [Abstract][Full Text] [Related]
16. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
Maurel J; Fra J; López-Pousa A; García del Muro X; Balañá C; Casado A; Martín J; Martínez-Trufero J; de las Peñas R; Buesa JM;
Cancer; 2004 Apr; 100(7):1498-506. PubMed ID: 15042685
[TBL] [Abstract][Full Text] [Related]
17. Implications of dose intensity for cancer clinical trials.
Semin Oncol; 1987 Dec; 14(4 Suppl 4):1-44. PubMed ID: 3686043
[No Abstract] [Full Text] [Related]
18. Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer.
Bonadonna G; Zambetti M; Moliterni A; Gianni L; Valagussa P
J Clin Oncol; 2004 May; 22(9):1614-20. PubMed ID: 15117983
[TBL] [Abstract][Full Text] [Related]
19. Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer.
Pérez-López ME; Curiel T; Gómez JG; Jorge M
Anticancer Drugs; 2007 Jun; 18(5):611-7. PubMed ID: 17414631
[TBL] [Abstract][Full Text] [Related]
20. Is high-dose intensity intraarterial cisplatin chemoradiotherapy for head and neck carcinoma feasible?
Robbins KT
Cancer; 2005 Feb; 103(3):447-50. PubMed ID: 15633205
[No Abstract] [Full Text] [Related]
[Next] [New Search]
